

**Supplemental Table 1. Crude and adjusted odds ratios for the association between ILD and variables in patients with CTD**

	OR (95% CI)	aOR (95% CI)
<b>Comorbidity</b>		
CCI without pulmonary disease	2.16 (1.42–3.30)	1.64 (1.03–2.62)
COPD	4.35 (2.92–6.48)	3.63 (2.38–5.54)
<b>Urbanisation</b>		
Level 1	Reference	
Level 2	0.89 (0.63–1.27)	
Level 3	0.80 (0.51–1.25)	
Level 4	0.88 (0.61–1.29)	
<b>Payroll-related insured amount, NTD</b>		
≤15,840	Reference	
15,841–20,100	1.15 (0.76–1.72)	
20,100–27,600	1.00 (0.69–1.46)	
≥27,600	0.94 (0.61–1.46)	
<b>Medication</b>		
Methotrexate	1.66 (1.17–2.37)	1.31 (0.87–1.96)
Sulphasalazine	1.31 (0.90–1.93)	0.86 (0.56–1.32)
Leflunomide	1.57 (0.91–2.71)	1.07 (0.57–1.99)
Hydroxychloroquine	1.59 (1.18–2.14)	1.31 (0.95–1.82)
Immunosuppressants	2.21 (1.50–3.27)	1.29 (0.83–2.01)
Steroid*, mg/day	1.13 (1.09–1.17)	1.11 (1.06–1.15)
Anti-TNF	2.10 (1.21–3.64)	1.25 (0.79–1.97)
Tocilizumab	8.00 (0.73–88.23)	1.46 (0.78–2.71)
Rituximab	2.55 (0.99–6.57)	8.11 (0.55–120.18)
<b>Air pollutants</b>		
PM2.5 (per 10 µg/m <sup>3</sup> )	0.71 (0.57–0.89)	0.71 (0.37–1.37)
PM10 (per 10 µg/m <sup>3</sup> )	0.82 (0.73–0.93)	1.10 (0.75–1.63)
SO <sub>2</sub> (per 10 ppb)	0.27 (0.08–0.94)	0.52 (0.10–2.68)
NO <sub>2</sub> (per 10 ppb)	1.04 (0.81–1.32)	
CO (per 1 ppm)	1.25 (0.69–2.26)	
O <sub>3</sub> (per 10 ppb)	0.54 (0.32–0.91)	0.47 (0.25–0.89)

\*Prednisolone equivalent. Abbreviations: ILD, interstitial lung disease; CCI, Charlson comorbidity index; COPD, chronic obstructive pulmonary disease; TNF, tumour necrosis factor; NA, not available; PM2.5, particulate matter <2.5 µm; PM10, particulate matter <10 µm; SO<sub>2</sub>, sulphur dioxide; NO<sub>2</sub>, nitrogen dioxide; CO, carbon monoxide; O<sub>3</sub>, ozone.